imatinib mesylate

Type: Keyphrase
Name: imatinib mesylate
First reported 12 mins ago - Updated 12 mins ago - 1 reports

Personalized Medicine Will Be 'One Size Fits Most' (Op-Ed)

By Mark Lawler, Queen's University BelfastDate: 27 August 2014 Time: 08:31 PM ETTreated as an individual.CREDIT: WhatmatdoesThis article was originally published at The Conversation. The publication contributed the article to Live Science's Expert Voices: ... [Published LiveScience.com - 12 mins ago]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

How science is using the genetics of disease to make drugs better

Treated as an individual. WhatmatdoesPersonalised medicine is the ability to tailor therapy to an individual patient so that, as it’s often put, the right treatment is given to the right patient at the right time. But just how personal is it?While the ... [Published Conversation UK - Aug 21 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Evaluating High-risk Clinicopathological Indicators in GIST

Steigen SE, Eide TJ: Gastrointestinal stromal tumors (GIST): a review. APMIS 2009, 117:73–86.Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG: Gastrointestinal stromal tumors: the incidence, prevalence, ... [Published General Medicine eJournal - Aug 11 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Military Strategies Being Used in the War on Cancer

Nearly everyone has heard of the War on Cancer, which was launched during the Nixon administration with the passage of the National Cancer Act of 1971. The goal of this legislation was to eradicate (or at least significantly decrease) the number of U.S. ... [Published Xconomy - Aug 04 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Methods and compositions for modulation of blood-neural barrier

Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic ... [Published PharmCast - Jul 17 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

[Comment] A modest but meaningful decision for Indian drug patents

On April 1, 2013, the Indian Supreme Court released its long-awaited decision on Novartis AG v Union of India & Others, better known as the Glivec (Gleevec in the USA; imatinib mesylate) patent case. Although neither the resounding victory for access ... [Published The Lancet online - Jun 27 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 1 reports

GLEEVEC (Imatinib Mesylate) Tablet [Novartis Pharmaceuticals Corporation]

First reported May 19 2014 - Updated May 19 2014 - 1 reports

Novartis agrees Gleevec patent deal

Novartis has settled patent litigation with Sun Pharmaceutical Industries in the US, paving the way for the Indian company’s subsidiary to launch a generic version of blockbuster blood cancer drug Gleevec next year.The basic compound patent for Gleevec ... [Published BioPortfolio - May 19 2014]
Entities: Gleevec, Novartis AG, Patent
First reported May 15 2014 - Updated May 16 2014 - 1 reports

Sun, Novartis settle dispute

Mumbai, May 15: Sun Pharma has settled a legal dispute with Novartis over blockbuster leukemia drug Gleevec in the US. The development will pave the way for Dilip Shanghvi-promoted Sun Pharma to launch a generic version of the drug in the US in 2016. ... [Published Calcutta Telegraph - May 15 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Antibody-based arrays for detecting multiple signal transducers in rate circulating cells

The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis ... [Published PharmCast - Mar 12 2014]

More Content

All (13) | News (10) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Personalized Medicine Will Be 'One Size Fits Mo... [Published LiveScience.com - 12 mins ago]
How science is using the genetics of disease to... [Published Conversation UK - Aug 21 2014]
Evaluating High-risk Clinicopathological Indica... [Published General Medicine eJournal - Aug 11 2014]
Military Strategies Being Used in the War on Ca... [Published Xconomy - Aug 04 2014]
Methods and compositions for modulation of bloo... [Published PharmCast - Jul 17 2014]
[Comment] A modest but meaningful decision for ... [Published The Lancet online - Jun 27 2014]
GLEEVEC (Imatinib Mesylate) Tablet [Novartis Ph... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
Novartis agrees Gleevec patent deal [Published BioPortfolio - May 19 2014]
Sun, Novartis settle dispute [Published Calcutta Telegraph - May 15 2014]
Antibody-based arrays for detecting multiple si... [Published PharmCast - Mar 12 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
BSE Healthcare index gains 22.6% during 2013, i... [Published PharmaBiz - Jan 03 2014]
Fact Sheet for SMS Pharmaceuticals Limited [Published Able2Act - May 06 2008]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Comment] A modest but meaningful decision for ... [Published The Lancet online - Jun 27 2014]
On April 1, 2013, the Indian Supreme Court released its long-awaited decision on Novartis AG v Union of India & Others, better known as the Glivec (Gleevec in the USA; imatinib mesylate) patent case. Although neither the resounding victory for access ...
GLEEVEC (Imatinib Mesylate) Tablet [Novartis Ph... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
Updated Date: May 29, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.